Q2FY23 Concall Notes
ARV formulations was down , pricing pressure in that business had let down the revenue guidance.we lost 500crs in H1 in ARV formulations.
Will not have more downgrade of guidance. We didnt not revise the pricing in tenders and lost a lot of tenders. Client side destocking over , we have visibility going forward.
75% of our business will not be impacted by European situation.
EBITDA margins was low because of lower margins in ARV API and deleverage in ARV formulation sales.
Newly commissioned FDF unit already shipping products. We have area left for another 5billion brownfield capacity expansion will take a call on it next year we can do it in 12M
against 24M incase of a greenfield.By the end of this FY23 we will have 75% utilization of 10billion FDF capacity ,less than 20% of new capacity was allocated to ARV business
Dedicated R&D block for a large Lifescience client will be commercially available next year september-october
Subscribe To Our Free Newsletter |